Seres Therapeutics Reports Positive Q1 2025 Results

Seres Therapeutics Inc. ( (MCRB) ) has released its Q1 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to its investors.

Seres Therapeutics, Inc. is a clinical-stage company specializing in live biotherapeutics aimed at improving outcomes for medically vulnerable populations, with a focus on developing treatments for bloodstream infections and inflammatory diseases. In its first quarter of 2025, Seres Therapeutics reported significant financial and strategic progress, highlighted by a net income of $32.7 million, a reversal from a net loss in the previous year, primarily due to a $50 million installment payment from Nestlé. The company is advancing its SER-155 program, which targets bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplants, with plans to submit a Phase 2 study protocol to the FDA soon. The Phase 1b study of SER-155 showed promising results, including a significant reduction in bloodstream infections, and the company is seeking strategic partnerships to support further development. Looking ahead, Seres Therapeutics is focused on expanding the application of its live biotherapeutics to other patient populations and is preparing for upcoming clinical studies and presentations, with a cash runway expected to fund operations into the first quarter of 2026.